Deep-tech firm ImVitro has introduced a $2.5M seed spherical led by LDV Capital, with co-investors together with MMC Ventures, Tiny VC, Fly Ventures, and Compound VC. The firm consists of a dozen consultants concerned with AI, medtech, and regulatory affairs. The crew is led by Dr. Alexandra Boussommier, a biomedical engineer educated in Switzerland, the UK and the US.
EMBRYOLY Platform for IVF Process
ImVitro developed the B2B SaaS platform EMBRYOLY, which applies pc imaginative and prescient and synthetic intelligence (AI) to the IVF fertility imaging course of. The firm works to attenuate failed transfers within the IVF course of, in addition to improve high quality management and transparency for sufferers.
Over a dozen clinics in Europe depend on EMBRYOLY, with greater than 1,500 IVF cycles being processed by the platform.
ImVitro developed an working system that mixes cell tradition and AI to handle infertility. The course of includes AI-powered automation within the embryo analysis course of with EMBRYOLY analyzing movies from microscopes to avoid wasting time for clinicians whereas rising transparency. This course of additionally eliminates human errors and delivers dependable predictions. Clinics may also use the platform to supply entry to a affected person portal that delivers simplified lab outcomes.
The platform is CE marked and has benchmarked its efficiency towards 13 embryologists in a retrospective scientific trial.
While different options are restricted to visible info or the affected person’s age, ImVitro can analyze greater than 30 scientific information factors to create a hybrid rating. These information factors embrace the affected person’s BMI, uterus receptivity, spermatozoa mobility, and extra. All of this results in improved accuracy and personalised and standardized outcomes.
Dr. Alexandra Boussommier can be Founder and CEO of ImVitro.
“By taking into account data about the patients and their treatment, EMBRYOLY predicts more accurately the chances an embryo has to lead to a pregnancy and provides more transparent and personalized recommendations,” Dr. Boussommier mentioned.
The new funding will go in the direction of including new hires within the technical and gross sales crew. It can even assist the corporate develop to the U.S. market and develop new options for the software program.
“We are very excited to be entering this new chapter that will consolidate our AI-driven software not only as a tool that minimizes failed IVF treatments, but also one that increases workflow efficiency in the IVF lab and provides a bridge between doctors and patients to add transparency to the complex multi-step process that is IVF,” Dr. Boussommier continued.
Dr. Xavier Pollet-Villard is Director of the Nataliance IVF and Andrology laboratory.
“ImVitro helps embryologists and patients at our clinic to navigate the complex process of IVF,” he says. “It not only increases the efficiency of the work that we do but also provides much-needed transparency. Their AI-powered platform EMBRYOLY seamlessly connects to our technology stack and helps us make data-driven decisions about embryos that we observe in our lab which then lead to successful pregnancies.”
Words From Investors
Evan Nisselson is Founder and General Partner at LDV Capital.
“We at LDV Capital are thrilled to partner with Dr. Alexandra Boussommier and the brilliant team at ImVitro to bring EMBRYOLY to market across the globe so millions of people can increase their likelihood of having a successful pregnancy through the IVF Fertility process,” mentioned Nisselson. “ImVitro will deliver a leapfrog technical solution to the IVF fertility imaging process by leveraging computer vision and artificial intelligence which has been a core expertise of our LDV Capital firm since being founded in 2012.”
Charlotte Barttelot is Principal at MMC Ventures.
“We’ve been researching the fertility landscape, and the IVF process has not improved since the first IVF baby over 40 years ago,” Barttelot mentioned. “ImVitro’s team combines deep-tech expertise and entrepreneurship, leveraging computer vision and AI to increase the percentage of successful pregnancies. We are proud to be part of their journey.”